Cancer Research Technology
Log in Register
Menu

Anti-LONP1 [LON20/H1]

Invented by Helen Turley from University of Oxford
Invented at University of Oxford

Info

Catalogue Number 152791
Applications ELISA IHC WB
Antigen/Gene or Protein Targets Human LON protease
Synonyms hLON, hLON ATP dependent protease, LON, LONP1, lon peptidase 1, mitochondrial, LON protease, Lon protease homolog, Lon protease like protein, Lon protease-like protein
Reactivity Human
Relevance ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. May also have a chaperone function in the assembly of inner membrane protein complexes. Participates in the regulation of mitochondrial gene expression and in the maintenance of the integrity of the mitochondrial genome. Binds to mitochondrial promoters and RNA in a single-stranded, site-specific, and strand-specific manner.
Host Mouse
Immunogen KLH-peptide conjugate - N-CEKDDKDAIEEKFRERLKE-C
Positive Control U87 cells
Subclass IgG
Molecular Weight (kDa) 106
Recommended Growing Conditions RPMI 10% FCS plus HAT essential
Research Area Cancer, Epigenetics & Nuclear Signalling, Metabolism

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Cameron Edward Snell PhD thesis, (2013). Mitochondrial modulators of hypoxia-related pathways in tumours. DPhil. University of Oxford.

IHC WB

Snell et al., 2016. Targeting the mitochondrial Lon protease reduces aerobic glycolysis and HIF-1a stabilisation in tumour cells. Submitted for publication.


Add a reference

References: 2 entries

Cameron Edward Snell PhD thesis, (2013). Mitochondrial modulators of hypoxia-related pathways in tumours. DPhil. University of Oxford.

IHC WB

Snell et al., 2016. Targeting the mitochondrial Lon protease reduces aerobic glycolysis and HIF-1a stabilisation in tumour cells. Submitted for publication.


Add a reference